{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:16:04Z","timestamp":1785417364116,"version":"3.56.0"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K08109"],"award-info":[{"award-number":["23K08109"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune checkpoint inhibitors (ICI) provide durable responses in a subset of colorectal cancers, yet benefit is largely confined to microsatellite instability\u2013high (MSI-H) tumors. We investigated whether the tumor-penetrating peptide iRGD enhances anti\u2013programmed cell death protein 1 (PD-1) treatment efficacy and examined the clinical relevance of neuropilin 1 (NRP1) expression. Syngeneic mouse models (MSI-H MC38 and microsatellite-stable CT26) were treated with an anti\u2013PD-1 antibody and iRGD. Tumor cell and stromal NRP1 contributions were compared using NRP1-knockout colorectal cancer cell lines. NRP1 expression was analyzed using immunohistochemistry in a consecutive cohort of 110 patients with stage III colorectal cancer who underwent curative surgery. iRGD and anti\u2013PD-1 antibody combination therapy enhanced antitumor effects in both colorectal cancer models, accompanied by increased intratumoral CD8+ T-cell abundance and improvements in their function. This effect persisted in tumors lacking tumor cell NRP1, suggesting that stromal NRP1 played a key role in mediating iRGD activity. In pathologic specimens from patients with colorectal cancer, widespread NRP1 expression was noted across tumor cells, the stromal compartment, and the vasculature, suggesting potential applicability of iRGD-based therapy in human colorectal cancer. Notably, stromal NRP1 expression was associated with poor overall and disease-free survival. Collectively, these findings position stromal NRP1 as a prognostic marker and an actionable entry point for iRGD-based ICI strategies, providing a strong rationale for their clinical development to extend the benefits of ICIs to broader colorectal cancer populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We demonstrated that iRGD enhanced anti\u2013PD-1 therapy efficacy in colorectal cancer models, improving intratumoral permeability and antitumor immune responses. NRP1 is broadly expressed across tumor compartments, and stromal, particularly endothelial, NRP1 is a key mediator of iRGD activity, associated with poor prognosis, representing a potential therapeutic entry point.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0619","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:52:48Z","timestamp":1779396768000},"page":"1364-1375","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing Immunotherapeutic Response in Colorectal Cancer with a Neuropilin 1\u2013Targeting Tumor-Penetrating Peptide"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2056-5848","authenticated-orcid":false,"given":"Atsushi","family":"Fukugaki","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kpeqv85","id-type":"ROR","asserted-by":"publisher"}],"name":"Kyoto University 1 Department of Surgery, Graduate School of Medicine, , Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-6978","authenticated-orcid":false,"given":"Shigeo","family":"Hisamori","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kpeqv85","id-type":"ROR","asserted-by":"publisher"}],"name":"Kyoto University 1 Department of Surgery, Graduate School of Medicine, , Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4513-8455","authenticated-orcid":false,"given":"Dean","family":"Thumkeo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kpeqv85","id-type":"ROR","asserted-by":"publisher"}],"name":"Kyoto University 2 Department of Immunopharmacology, Graduate School of Medicine, , Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7728-4494","authenticated-orcid":false,"given":"Hotaka","family":"Kawai","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pc6pc55","id-type":"ROR","asserted-by":"publisher"}],"name":"Okayama University 3 Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, , Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9442-2279","authenticated-orcid":false,"given":"Yugo","family":"Matsui","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kpeqv85","id-type":"ROR","asserted-by":"publisher"}],"name":"Kyoto University 1 Department of Surgery, Graduate School of Medicine, , Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8620-0710","authenticated-orcid":false,"given":"Yuki","family":"Teramoto","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kpeqv85","id-type":"ROR","asserted-by":"publisher"}],"name":"Kyoto University 4 Department of Diagnostic Pathology, Graduate School of Medicine, , Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-6990","authenticated-orcid":false,"given":"Yoshihisa","family":"Okuchi","sequence":"additional","affiliation":[{"name":"5Department of Gastroenterological Surgery and Oncology, Medical Research Institute Kitano Hospital, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6479-9446","authenticated-orcid":false,"given":"Atsuhito","family":"Omori","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kpeqv85","id-type":"ROR","asserted-by":"publisher"}],"name":"Kyoto University 1 Department of Surgery, Graduate School of Medicine, , Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2251-3408","authenticated-orcid":false,"given":"Norio","family":"Miyamura","sequence":"additional","affiliation":[{"name":"6Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6920-6731","authenticated-orcid":false,"given":"Yukihito","family":"Kuroda","sequence":"additional","affiliation":[{"name":"6Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4946-192X","authenticated-orcid":false,"given":"Kazuki N.","family":"Sugahara","sequence":"additional","affiliation":[{"name":"6Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2924-6701","authenticated-orcid":false,"given":"Kazutaka","family":"Obama","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kpeqv85","id-type":"ROR","asserted-by":"publisher"}],"name":"Kyoto University 1 Department of Surgery, Graduate School of Medicine, , Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026061006015976900_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026061006015976900_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2017.09.016","article-title":"Overcoming key biological barriers to cancer drug delivery and efficacy","volume":"267","author":"Kim","year":"2017","journal-title":"J Control Release"},{"key":"2026061006015976900_bib3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"key":"2026061006015976900_bib4","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1073\/pnas.0908201106","article-title":"C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration","volume":"106","author":"Teesalu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026061006015976900_bib5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science"},{"key":"2026061006015976900_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1535-7163.MCT-14-0366","article-title":"Tumor-penetrating iRGD peptide inhibits metastasis","volume":"14","author":"Sugahara","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2026061006015976900_bib7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.biopha.2017.06.103","article-title":"Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells","volume":"93","author":"Zhang","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2026061006015976900_bib8","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.2147\/IJN.S219820","article-title":"Co-administration of iRGD enhances tumor-targeted delivery and anti-tumor effects of paclitaxel-loaded PLGA nanoparticles for colorectal cancer treatment","volume":"14","author":"Zhong","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"2026061006015976900_bib9","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1039\/C8TB00319J","article-title":"Co-administration of biocompatible self-assembled polylactic acid-hyaluronic acid block copolymer nanoparticles with tumor-penetrating peptide-iRGD for metastatic breast cancer therapy","volume":"6","author":"Deng","year":"2018","journal-title":"J Mater Chem B"},{"key":"2026061006015976900_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman","year":"2009","journal-title":"Br J Cancer"},{"key":"2026061006015976900_bib11","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026061006015976900_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.23922\/jarc.2020-064","article-title":"Immunotherapy in colorectal cancer: current and future strategies","volume":"5","author":"Ooki","year":"2021","journal-title":"J Anus Rectum Colon"},{"key":"2026061006015976900_bib13","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.dld.2021.06.009","article-title":"Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: the FFCD 1703-POCHI trial","volume":"53","author":"Gallois","year":"2021","journal-title":"Dig Liver Dis"},{"key":"2026061006015976900_bib14","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026061006015976900_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41392-024-01794-4","article-title":"Anti-lymphangiogenesis for boosting drug accumulation in tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026061006015976900_bib16","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41467-019-09296-6","article-title":"iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer","volume":"10","author":"Ding","year":"2019","journal-title":"Nat Commun"},{"key":"2026061006015976900_bib17","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/bjc.2014.49","article-title":"Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1","volume":"110","author":"Akashi","year":"2014","journal-title":"Br J Cancer"},{"key":"2026061006015976900_bib18","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.7150\/jca.52851","article-title":"Neuropilin-1 predicts poor prognosis and promotes tumor metastasis through epithelial-mesenchymal transition in gastric cancer","volume":"12","author":"Jin","year":"2021","journal-title":"J Cancer"},{"key":"2026061006015976900_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41419-023-05696-1","article-title":"NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis"},{"key":"2026061006015976900_bib20","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.3390\/cancers14143455","article-title":"Neuropilin-1 as a potential biomarker of prognosis and invasive-related parameters in liver and colorectal cancer: a systematic review and meta-analysis of human studies","volume":"14","author":"Fern\u00e1ndez-Palanca","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026061006015976900_bib21","first-page":"369","article-title":"The preserved expression of neuropilin (NRP) 1 contributes to a better prognosis in colon cancer","volume":"15","author":"Kamiya","year":"2006","journal-title":"Oncol Rep"},{"key":"2026061006015976900_bib22","first-page":"105","article-title":"Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer","volume":"29","author":"Ochiumi","year":"2006","journal-title":"Int J Oncol"},{"key":"2026061006015976900_bib23","doi-asserted-by":"crossref","first-page":"1758835920928635","DOI":"10.1177\/1758835920928635","article-title":"Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC","volume":"12","author":"Bianconi","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2026061006015976900_bib24","doi-asserted-by":"crossref","first-page":"e000967","DOI":"10.1136\/jitc-2020-000967","article-title":"Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy","volume":"8","author":"Chuckran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026061006015976900_bib25","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2026061006015976900_bib26","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026061006015976900_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"2026061006015976900_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41467-017-02424-0","article-title":"Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution","volume":"9","author":"Efremova","year":"2018","journal-title":"Nat Commun"},{"key":"2026061006015976900_bib29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13046-021-02043-0","article-title":"Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth","volume":"40","author":"Doleschel","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026061006015976900_bib30","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1172\/JCI92284","article-title":"Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer","volume":"127","author":"Liu","year":"2017","journal-title":"J Clin Invest"},{"key":"2026061006015976900_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00262-024-03925-w","article-title":"IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization","volume":"74","author":"Guangzhao","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"2026061006015976900_bib32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2026061006015976900_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"2026061006015976900_bib34","doi-asserted-by":"crossref","first-page":"eabc2777","DOI":"10.1126\/sciadv.abc2777","article-title":"Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy","volume":"6","author":"Nguyen","year":"2020","journal-title":"Sci Adv"},{"key":"2026061006015976900_bib35","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/01.RES.0000171756.13554.49","article-title":"Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability","volume":"96","author":"Becker","year":"2005","journal-title":"Circ Res"},{"key":"2026061006015976900_bib36","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1182\/blood-2007-08-110205","article-title":"Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor","volume":"111","author":"Acevedo","year":"2008","journal-title":"Blood"},{"key":"2026061006015976900_bib37","doi-asserted-by":"crossref","first-page":"13493","DOI":"10.1074\/jbc.M512121200","article-title":"Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling","volume":"281","author":"Jia","year":"2006","journal-title":"J Biol Chem"},{"key":"2026061006015976900_bib38","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.lfs.2006.08.005","article-title":"Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1","volume":"79","author":"Starzec","year":"2006","journal-title":"Life Sci"},{"key":"2026061006015976900_bib39","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1007\/s13346-021-01036-y","article-title":"Overcoming physical stromal barriers to cancer immunotherapy","volume":"11","author":"Chung","year":"2021","journal-title":"Drug Deliv Transl Res"},{"key":"2026061006015976900_bib40","doi-asserted-by":"crossref","first-page":"101731","DOI":"10.1016\/j.jhepr.2026.101731","article-title":"Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma","volume":"8","author":"Klug","year":"2026","journal-title":"JHEP Rep"},{"key":"2026061006015976900_bib41","doi-asserted-by":"crossref","first-page":"e2105323118","DOI":"10.1073\/pnas.2105323118","article-title":"Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy","volume":"118","author":"Ho","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026061006015976900_bib42","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/s41416-023-02392-x","article-title":"Advancing translational research for colorectal immuno-oncology","volume":"129","author":"Thomas","year":"2023","journal-title":"Br J Cancer"},{"key":"2026061006015976900_bib43","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41419-021-03672-1","article-title":"Impaired AGO2\/miR-185-3p\/NRP1 axis promotes colorectal cancer metastasis","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"key":"2026061006015976900_bib44","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1038\/bjc.2013.649","article-title":"Prognostic\/predictive value of 207 serum factors in colorectal cancer treated with cediranib and\/or chemotherapy","volume":"109","author":"Spencer","year":"2013","journal-title":"Br J Cancer"},{"key":"2026061006015976900_bib45","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-15-3117","article-title":"BATON-CRC: a phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer","volume":"22","author":"Benson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026061006015976900_bib46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","article-title":"Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor","volume":"92","author":"Soker","year":"1998","journal-title":"Cell"},{"key":"2026061006015976900_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2006.10.018","article-title":"Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth","volume":"11","author":"Pan","year":"2007","journal-title":"Cancer Cell"},{"key":"2026061006015976900_bib48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.bjc.6605539","article-title":"Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity","volume":"102","author":"Jia","year":"2010","journal-title":"Br J Cancer"},{"key":"2026061006015976900_bib49","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.4161\/cbt.6.8.4363","article-title":"Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion","volume":"6","author":"Fukasawa","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"2026061006015976900_bib50","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s11307-017-1051-4","article-title":"Characterization of an orthotopic colorectal cancer mouse model and its feasibility for accurate quantification in positron emission tomography","volume":"19","author":"Rapic","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"2026061006015976900_bib51","doi-asserted-by":"crossref","first-page":"108631","DOI":"10.1016\/j.pharmthera.2024.108631","article-title":"Orthotopic and metastatic tumour models in preclinical cancer research","volume":"257","author":"Stribbling","year":"2024","journal-title":"Pharmacol Ther"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0619\/3796663\/crc-25-0619.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/6\/1364\/3802728\/crc-25-0619.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/6\/1364\/3802728\/crc-25-0619.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:02:13Z","timestamp":1781085733000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/6\/1364\/785752\/Enhancing-Immunotherapeutic-Response-in-Colorectal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0619","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32627641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32627620","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32627632","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32627644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32627623","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32627635","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32627647","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32627650","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32627626","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32627638","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32627629","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8528521","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}